Jean L Wright1, Cristiane Takita2, Isildinha M Reis3, Wei Zhao4, Eunkyung Lee4, Jennifer J Hu3. 1. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland. Electronic address: jwrigh71@jhmi.edu. 2. Department of Radiation Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida. 3. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida; Department of Public Health Sciences, University of Miami, Miami, Florida. 4. Department of Public Health Sciences, University of Miami, Miami, Florida.
Abstract
PURPOSE: Radiation-induced skin toxicity is one of the most symptomatic side effects of postmastectomy radiation therapy (PMRT). We sought to determine whether the severity of acute skin toxicity was greater in black patients in a prospective cohort receiving PMRT and to identify other predictors of more severe skin toxicity. METHODS AND MATERIALS: We evaluated the first 110 patients in an ongoing prospective study assessing radiation-induced skin toxicity in patients receiving PMRT. We recorded patient demographics, body mass index (BMI), and disease and treatment characteristics. Logistic regression analyses were conducted to evaluate the effect of potential predictors on the risk of skin toxicity. RESULTS: A total of 23.6% respondents self-identified as black, 5.5% as non-Hispanic white, 69.1% as Hispanic white, and 1.8% as other; 57% were postmenopausal, and 70.9% had BMI of >25. Median chest wall dose was 50 Gy, and mastectomy scar dose was 60 Gy. Most patients, 95.5%, were treated with a 0.5-cm bolus throughout treatment. There were no significant differences in patient characteristics in black versus non-black patients. At RT completion, moist desquamation was more common in black patients (73.1% vs 47.6%, respectively, P=.023), in postmenopausal patients (63.5% vs 40.4%, respectively, P=.016), and in those with BMI of ≥25 (60.3% vs 37.5%, respectively, P=.030). On multivariate analysis, the effects of black race (odds ratio [OR] = 7.46, P=.031), BMI ≥25 (OR = 2.95, P=.043) and postmenopausal status (OR = 8.26, P=.004) remained significant risk factors for moist desquamation. CONCLUSIONS: In this prospectively followed, racially diverse cohort of breast cancer patients receiving PMRT delivered in a uniform fashion, including the routine use of chest wall boost and bolus, black race, higher BMI, and postmenopausal status emerged as significant predictors of moist desquamation. There was a high frequency of moist desquamation, particularly in those patients with elevated risk. Continued study of patient selection for chest wall boost and bolus as well improved skin toxicity management strategies are needed.
PURPOSE: Radiation-induced skin toxicity is one of the most symptomatic side effects of postmastectomy radiation therapy (PMRT). We sought to determine whether the severity of acute skin toxicity was greater in black patients in a prospective cohort receiving PMRT and to identify other predictors of more severe skin toxicity. METHODS AND MATERIALS: We evaluated the first 110 patients in an ongoing prospective study assessing radiation-induced skin toxicity in patients receiving PMRT. We recorded patient demographics, body mass index (BMI), and disease and treatment characteristics. Logistic regression analyses were conducted to evaluate the effect of potential predictors on the risk of skin toxicity. RESULTS: A total of 23.6% respondents self-identified as black, 5.5% as non-Hispanic white, 69.1% as Hispanic white, and 1.8% as other; 57% were postmenopausal, and 70.9% had BMI of >25. Median chest wall dose was 50 Gy, and mastectomy scar dose was 60 Gy. Most patients, 95.5%, were treated with a 0.5-cm bolus throughout treatment. There were no significant differences in patient characteristics in black versus non-black patients. At RT completion, moist desquamation was more common in black patients (73.1% vs 47.6%, respectively, P=.023), in postmenopausal patients (63.5% vs 40.4%, respectively, P=.016), and in those with BMI of ≥25 (60.3% vs 37.5%, respectively, P=.030). On multivariate analysis, the effects of black race (odds ratio [OR] = 7.46, P=.031), BMI ≥25 (OR = 2.95, P=.043) and postmenopausal status (OR = 8.26, P=.004) remained significant risk factors for moist desquamation. CONCLUSIONS: In this prospectively followed, racially diverse cohort of breast cancerpatients receiving PMRT delivered in a uniform fashion, including the routine use of chest wall boost and bolus, black race, higher BMI, and postmenopausal status emerged as significant predictors of moist desquamation. There was a high frequency of moist desquamation, particularly in those patients with elevated risk. Continued study of patient selection for chest wall boost and bolus as well improved skin toxicity management strategies are needed.
Authors: Dhaval J Shah; Ram Hirpara; Corrie L Poelman; Adrianne Woods; Laura K Hummers; Fredrick M Wigley; Jean L Wright; Arti Parekh; Virginia D Steen; Robyn T Domsic; Ami A Shah Journal: Arthritis Care Res (Hoboken) Date: 2018-10 Impact factor: 4.794
Authors: Jennifer J Hu; James J Urbanic; L Doug Case; Cristiane Takita; Jean L Wright; Doris R Brown; Carl D Langefeld; Mark O Lively; Sandra E Mitchell; Anu Thakrar; David Bryant; Kathy Baglan; Jon Strasser; Luis Baez-Diaz; Glenn J Lesser; Edward G Shaw Journal: J Clin Oncol Date: 2018-07-10 Impact factor: 44.544
Authors: Katherine E Reeder-Hayes; Sophie E Mayer; Andrew F Olshan; Stephanie B Wheeler; Lisa A Carey; Chiu-Kit Tse; Mary Elizabeth Bell; Melissa A Troester Journal: Cancer Date: 2019-08-09 Impact factor: 6.860
Authors: Eunkyung Lee; Cristiane Takita; Jean L Wright; Isildinha M Reis; Wei Zhao; Omar L Nelson; Jennifer J Hu Journal: Pain Date: 2016-05 Impact factor: 7.926
Authors: Leslie A Modlin; Jessica Flynn; Zhigang Zhang; Oren Cahlon; Boris Mueller; Atif J Khan; Erin F Gillespie; Beryl McCormick; Zsofia K Stadler; Mark E Robson; Simon N Powell; Lior Z Braunstein Journal: JCO Precis Oncol Date: 2021-01-19